A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.